|
|
| (4 intermediate revisions by the same user not shown) |
| Line 4: |
Line 4: |
| {{Under Construction}} | | {{Under Construction}} |
|
| |
|
| <blockquote class='blockedit'>{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Cutaneous Mastocytosis]]. | | <blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Cutaneous Mastocytosis]]. |
| }}</blockquote> | | }}</blockquote> |
|
| |
|
| Line 12: |
Line 12: |
|
| |
|
| S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD | | S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD |
|
| |
| __TOC__
| |
|
| |
| ==WHO Classification of Disease== | | ==WHO Classification of Disease== |
|
| |
|
| Line 37: |
Line 34: |
| |} | | |} |
|
| |
|
| ==Definition / Description of Disease== | | ==Related Terminology== |
| | |
| Cutaneous mastocytosis is a mast cell disorder that primarily affects the skin.
| |
| | |
| ==Synonyms / Terminology==
| |
| | |
| Urticaria pigmentosa
| |
| | |
| ==Epidemiology / Prevalence==
| |
|
| |
|
| Cutaneous mastocytosis (CM) most commonly affect children, which is usually diagnosed prior to 2 years old with slight male predominance <ref>{{Cite journal|last=Castells|first=Mariana|last2=Metcalfe|first2=Dean D.|last3=Escribano|first3=Luis|date=2011-08-01|title=Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations|url=https://pubmed.ncbi.nlm.nih.gov/21668033|journal=American Journal of Clinical Dermatology|volume=12|issue=4|pages=259–270|doi=10.2165/11588890-000000000-00000|issn=1179-1888|pmc=4126834|pmid=21668033}}</ref><ref>{{Cite journal|last=Hartmann|first=Karin|last2=Henz|first2=Beate M.|date=2002-02|title=Cutaneous mastocytosis -- clinical heterogeneity|url=https://pubmed.ncbi.nlm.nih.gov/11919426|journal=International Archives of Allergy and Immunology|volume=127|issue=2|pages=143–146|doi=10.1159/000048187|issn=1018-2438|pmid=11919426}}</ref>. Approximately 80% of patient of mastocytosis develop cutaneous lesion <ref>{{Cite journal|last=Pardanani|first=A.|last2=Akin|first2=C.|last3=Valent|first3=P.|date=2006|title=Pathogenesis, clinical features, and treatment advances in mastocytosis|url=https://pubmed.ncbi.nlm.nih.gov/16781490|journal=Best Practice & Research. Clinical Haematology|volume=19|issue=3|pages=595–615|doi=10.1016/j.beha.2005.07.010|issn=1521-6926|pmid=16781490}}</ref>.
| |
|
| |
| ==Clinical Features==
| |
|
| |
| Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table. Do not delete table.'') </span>
| |
| {| class="wikitable"
| |
| |'''Signs and Symptoms'''
| |
| |<span class="blue-text">EXAMPLE:</span> Asymptomatic (incidental finding on complete blood counts)
| |
|
| |
| <span class="blue-text">EXAMPLE:</span> B-symptoms (weight loss, fever, night sweats)
| |
|
| |
| <span class="blue-text">EXAMPLE:</span> Fatigue
| |
|
| |
| <span class="blue-text">EXAMPLE:</span> Lymphadenopathy (uncommon)
| |
| |-
| |
| |'''Laboratory Findings'''
| |
| |<span class="blue-text">EXAMPLE:</span> Cytopenias
| |
|
| |
| <span class="blue-text">EXAMPLE:</span> Lymphocytosis (low level)
| |
| |}
| |
|
| |
|
| |
| <blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}</blockquote>
| |
|
| |
| There are three typical variants of cutaneous mastocytosis: 1) urticaria pigmentosa (UP)/maculopapular cutaneous mastocytosis (MPCM), 2) diffuse CM, and 3) mastocytoma of skin. UP/MPCM is the most common type and presents as brown or red macule or macule and papules with melanin pigmentation. Diffuse CM is almost exclusively in childhood and presents as diffusely thickened skin, pachydermia. Familial cases and germline mutations can be associated diffuse CM. Cutaneous mastocytoma is also known as solitary mastocytoma of skin, which is single or less than 3 lesions without predilection for presenting site. In addition, CM cannot be diagnosed if the features or criteria of systemic mastocytosis are met.
| |
|
| |
| <blockquote class="blockedit">
| |
| <center><span style="color:Maroon">'''End of V4 Section'''</span>
| |
| ----
| |
| </blockquote>
| |
| ==Sites of Involvement==
| |
|
| |
| Cutaneous mastocytosis can present in any location of the body with common involvement of extremities and trunk.
| |
|
| |
| ==Morphologic Features==
| |
|
| |
| Histologically, CM demonstrates increased number of mast cells in skin lesion. UP/MPCM reveals spindle-shaped mast cells in papillary dermis with extension to reticular dermis. Diffuse CM demonstrate highest number of mast cells in sheets filling papillary and upper reticular dermis. Cutaneous mastocytoma usually involves subcutaneous tissue with abundant granular cytoplasm of mast cells.
| |
|
| |
| ==Immunophenotype==
| |
|
| |
| Put your text here and/or fill in the table
| |
|
| |
| {| class="wikitable sortable"
| |
| |-
| |
| !Finding!!Marker
| |
| |-
| |
| |Positive (universal)||CD117; Tryptase
| |
| |-
| |
| |Positive (subset)||Aberrant CD25 and CD2; CD30 in well-differentiated mastocytosis
| |
| |-
| |
| |Negative (universal)||B-cell antigens; CD3; CD5; CD7; MPO; CD15; CD21; CD34
| |
| |}
| |
| ==WHO Essential and Desirable Genetic Diagnostic Criteria==
| |
| <span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
| |
| {| class="wikitable"
| |
| |+
| |
| |WHO Essential Criteria (Genetics)*
| |
| |
| |
| |-
| |
| |WHO Desirable Criteria (Genetics)*
| |
| |
| |
| |-
| |
| |Other Classification
| |
| |
| |
| |}
| |
| <nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
| |
| ==Related Terminology==
| |
| <span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>
| |
| {| class="wikitable" | | {| class="wikitable" |
| |+ | | |+ |
| |Acceptable | | |Acceptable |
| | | | |N/A |
| |- | | |- |
| |Not Recommended | | |Not Recommended |
| | | | |Urticaria pigmentosa; telangiectasia macularis eruptiva perstans |
| |} | | |} |
|
| |
|
| Line 192: |
Line 113: |
| {| class="wikitable sortable" | | {| class="wikitable sortable" |
| |- | | |- |
| !Chr #!!'''Gain, Loss, Amp, LOH'''!!'''Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]'''!!'''Relevant Gene(s)''' | | !Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s) |
| !'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T''' | | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T |
| !'''Established Clinical Significance Per Guidelines - Yes or No (Source)''' | | !Established Clinical Significance Per Guidelines - Yes or No (Source) |
| !'''Clinical Relevance Details/Other Notes''' | | !Clinical Relevance Details/Other Notes |
| |- | | |- |
| |<span class="blue-text">EXAMPLE:</span> | | |<span class="blue-text">EXAMPLE:</span> |
| Line 249: |
Line 170: |
| !Chromosomal Pattern | | !Chromosomal Pattern |
| !Molecular Pathogenesis | | !Molecular Pathogenesis |
| !'''Prevalence -''' | | !Prevalence - |
| '''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
| | Common >20%, Recurrent 5-20% or Rare <5% (Disease) |
| !'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T''' | | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T |
| !'''Established Clinical Significance Per Guidelines - Yes or No (Source)''' | | !Established Clinical Significance Per Guidelines - Yes or No (Source) |
| !'''Clinical Relevance Details/Other Notes''' | | !Clinical Relevance Details/Other Notes |
| |- | | |- |
| |<span class="blue-text">EXAMPLE:</span> | | |<span class="blue-text">EXAMPLE:</span> |
| Line 284: |
Line 205: |
| {| class="wikitable sortable" | | {| class="wikitable sortable" |
| |- | | |- |
| !Gene!!'''Genetic Alteration'''!!'''Tumor Suppressor Gene, Oncogene, Other'''!!'''Prevalence -''' | | !Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence - |
| '''Common >20%, Recurrent 5-20% or Rare <5% (Disease)'''
| | Common >20%, Recurrent 5-20% or Rare <5% (Disease) |
| !'''Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ''' | | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T |
| !'''Established Clinical Significance Per Guidelines - Yes or No (Source)''' | | !Established Clinical Significance Per Guidelines - Yes or No (Source) |
| !'''Clinical Relevance Details/Other Notes''' | | !Clinical Relevance Details/Other Notes |
| |- | | |- |
| |<span class="blue-text">EXAMPLE:</span>''EGFR'' | | |<span class="blue-text">EXAMPLE:</span>''EGFR'' |
| Line 326: |
Line 247: |
| |}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | | |}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. |
|
| |
|
| <blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote> | | <blockquote class="blockedit">{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}</blockquote> |
|
| |
|
| Put your text here and/or fill in the tables | | Put your text here and/or fill in the tables |
| Line 649: |
Line 570: |
| (use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references /> | | (use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references /> |
|
| |
|
| '''
| | <br /> |
|
| |
|
| ==Notes== | | ==Notes== |
| Line 658: |
Line 579: |
| | | |
| <nowiki>*</nowiki>''Citation of this Page'': “Cutaneous mastocytosis”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Cutaneous_mastocytosis</nowiki>. | | <nowiki>*</nowiki>''Citation of this Page'': “Cutaneous mastocytosis”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Cutaneous_mastocytosis</nowiki>. |
| [[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases C]] | | [[Category:HAEM5]] |
| | [[Category:DISEASE]] |
| | [[Category:Diseases C]] |